Brick 42 connects global pharma players to solve complex sourcing and manufacturing challenges — oncology APIs, oligonucleotides, long-acting injectables, biologicals. Project-based. Consultative. End-to-end.
$250B+ in patent cliffs approaching. The shift from small molecules to complex generics and biosimilars. Excellent chemistry emerging from India and China — but navigating the supply chain is another story entirely.
Blockbuster drugs losing exclusivity over the next five years. Generic manufacturers need reliable sourcing for complex APIs — fast.
Most pharmaceutical supply chains span 3–5 countries. Quality, logistics, and regulatory compliance across borders remain the core challenge.
Oncology, oligonucleotides, long-acting injectables. The molecules getting off-patent are fundamentally harder to source and manufacture.
We don't list molecules in a spreadsheet. We take your sourcing challenge, map the global landscape, qualify manufacturing partners, and manage the project through to delivery.
We identify and qualify API manufacturers across India, China, Europe, and the US. Deep relationships, not just databases — we know who can actually deliver.
Regulatory audits, capacity assessments, quality system reviews. We vet every supplier against EU/US GMP standards before they enter your supply chain.
From feasibility through commercial supply. We manage timelines, logistics, regulatory submissions, and stakeholder coordination across every participant in the chain.
FDA, EMA, Swissmedic, PMDA. We understand the submission requirements for each market and ensure your API sourcing strategy is built for global registration.
Large-scale API suppliers focus on high-volume, simple chemistry. That leaves a gap: complex molecules with smaller initial volumes but critical therapeutic value. Brick 42 fills that gap — connecting the right chemistry capabilities with the right commercial partners.
Our network specializes in the molecule categories that large suppliers avoid — because the synthesis is complex, the volumes are specialized, and the regulatory bar is high.
High-potency active pharmaceutical ingredients for cancer treatment. Cytotoxic agents requiring specialized containment and handling.
Next-generation antisense therapies and siRNA. Specialized synthesis requiring nucleotide chemistry expertise and GMP-grade purification.
Complex formulation and API sourcing for depot injections with sustained release profiles. Requires tight particle size and purity specs.
Biosimilar components and therapeutic enzymes. Bridging the gap between traditional small molecules and full biologics manufacturing.
We're based in Lugano for a reason. Switzerland offers regulatory credibility, geopolitical neutrality, and direct access to European pharma decision-makers.
Switzerland sits at the crossroads of global pharma. Indian API manufacturers, Chinese CDMO partners, European generics companies, and US buyers — we bring them together on trusted, neutral territory.
We've spent decades building relationships across the pharmaceutical supply chain. Our network isn't a list of contacts — it's a web of trusted partnerships tested across real projects.
No retainers, no open-ended engagements. Every project has defined scope, timelines, and deliverables. You pay for outcomes, not hours. We succeed when your supply chain works.
Whether you're looking at a specific molecule, planning for a patent cliff opportunity, or need to diversify your API supply chain — we'll tell you straight if we can help.
Book a Meeting →Calendly booking link coming soon. For now, email us directly.